Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|June 27, 2022
Daily OTC Pearl: All Natural Acid Indigestion Relief
Author(s)Saro Arakelians, PharmD
Maty's All Natural Acid and Indigestion Relief is an alternative to traditional antacid tablets to relieve indigestion and heartburn.
Advertisement
OTC/Lifestyle Pearl of the Day: All Natural Acid Indigestion Relief
Indication: Maty's All Natural Acid and Indigestion Relief is an alternative to traditional antacid tablets to relieve indigestion and heartburn.
Insight:
- This heartburn remedy is drug-free and made with natural ingredients.
- Some of the ingredients include apple cider vinegar, ginger, and turmeric.
- Can be taken for occasional heartburn relief, indigestion relief, acid relief, or as a daily digestive supplement.
Source:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5